DiagnoCure Q4 Revenues Slide 59 Percent, Terminates Deal with Signal Genetics
January 14, 2013
DiagnoCure Q4 Revenues Slide 59 Percent, Terminates Deal with Signal Genetics
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- DiagnoCure Posts Sharp Q3 Revenue Increase; Warns It May Not Receive Payment for Services Rendered
September 6, 2012 / GenomeWeb Daily News - FDA Approves Gen-Probe's Assay for Prostate Cancer
February 15, 2012 / GenomeWeb Daily News - Gen-Probe to File PMA for PCA3 Assay; Possible Alternative to PSA
September 2, 2009 / Pharmacogenomics Reporter - Gen-Probe Acquisition Drives up Hologic's Q2 Revenues 30 Percent
May 6, 2013 / GenomeWeb Daily News - Cepheid Highlights Strong Uptake of Xpert CT/NG as Q1 Revenues Rise 19 Percent
April 25, 2013 / PCR Insider